C&EN’s Year in Pharma 2022: The roller-coaster ride continued for Alzheimer’s drug candidates
By Even with the field’s multiple setbacks, Alzheimer’s experts still count 2022 as an exciting year
Hit enter after type your search item
Even with the field’s multiple setbacks, Alzheimer’s experts still count 2022 as an exciting year
